ASCO China Voice | World’s First HOPE-07 Trial Launched: Disitamab Vedotin–Based Combination Poised to Redefine Perioperative Management of HER2-Expressing MIBC 

ASCO China Voice | World’s First HOPE-07 Trial Launched: Disitamab Vedotin–Based Combination Poised to Redefine Perioperative Management of HER2-Expressing MIBC 

Following the clinical success and approval of disitamab vedotin (RC48) plus toripalimab in locally advanced or metastatic urothelial carcinoma, attention has shifted toward improving outcomes for patients with muscle-invasive bladder cancer (MIBC) in the perioperative setting, where substantial unmet clinical needs remain.
ASCO 2026 | Prof. Pedro C. Barata: Safety and Dosimetry Results of TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan) in mCRPC 

ASCO 2026 | Prof. Pedro C. Barata: Safety and Dosimetry Results of TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan) in mCRPC 

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting once again brought together the latest advances in cancer research from around the world. Among the most closely watched areas was radioligand therapy (RLT) for prostate cancer. During the meeting, the ProstACT Global 3 study team presented the first Part 1 results from its Phase III trial, focusing on the safety and dosimetry of TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan). These findings provide early evidence supporting the feasibility of integrating TLX591 with standard-of-care treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), while also demonstrating encouraging preliminary efficacy signals.
2-Year PFS Rate Significantly Improved by 8.2%! FRONTMIND Study Confirms Tafa+Len+R-CHOP Improves Prognosis in Previously Untreated High-Risk DLBCL Patients 

2-Year PFS Rate Significantly Improved by 8.2%! FRONTMIND Study Confirms Tafa+Len+R-CHOP Improves Prognosis in Previously Untreated High-Risk DLBCL Patients 

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Georg Lenz from the University of Münster, Germany, on behalf of the FRONTMIND study group, delivered an oral presentation on the final analysis results of the Phase 3 FRONTMIND study. This study aimed to investigate the efficacy and safety of adding the CD19 monoclonal antibody Tafasitamab and the immunomodulatory drug Lenalidomide to the standard R-CHOP regimen (hereafter referred to as Tafa-Len+R-CHOP) for the frontline treatment of patients with high-risk diffuse large B-cell lymphoma (DLBCL).
From Genetic Drivers to Precision Prevention: Professor George Vassiliou Awarded the EHA Research Excellence Award, Leading a Shift in Myeloid Malignancy Prevention and Treatment 

From Genetic Drivers to Precision Prevention: Professor George Vassiliou Awarded the EHA Research Excellence Award, Leading a Shift in Myeloid Malignancy Prevention and Treatment 

At the 2026 European Hematology Association (EHA) Annual Meeting, the association presented the "EHA Research Excellence Award" to Professor George Vassiliou from the University of Cambridge and the Wellcome Sanger Institute, in recognition of his pioneering contributions to the fields of biology, pathogenesis, and early intervention in myeloid malignancies. In the subsequent award lecture, Professor Vassiliou reviewed the landmark research conducted by his team over the past 15 years regarding the identification of driver genes in acute myeloid leukemia (AML), the evolutionary logic of clonal hematopoiesis (CH), and the development of clinical prediction tools.
EHA 2026 Clinical Excellence Awardee Prof. Josep Maria Ribera: Crossing 40 Years to Open a New Era of Precision Treatment for Acute Lymphoblastic Leukemia 

EHA 2026 Clinical Excellence Awardee Prof. Josep Maria Ribera: Crossing 40 Years to Open a New Era of Precision Treatment for Acute Lymphoblastic Leukemia 

At the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Josep Maria Ribera from the Josep Carreras Leukemia Research Institute and the Catalan Institute of Oncology (ICO) was honored with the "EHA Clinical Excellence Award." In his subsequent award lecture, Prof. Ribera systematically reviewed the successful transformation of Acute Lymphoblastic Leukemia (ALL) from a "diagnostic deficiency period" to a "precision immunotherapy period," shared the successful experiences of the Spanish PETEMA group, and outlined a future "chemo-free" treatment blueprint.
EHA 2026 Highlight: Prof. Lars Bullinger Deciphers 25 Years of Molecular Hematology Evolution—From Gene Expression Profiles to Precision Diagnosis and Treatment Profiles

EHA 2026 Highlight: Prof. Lars Bullinger Deciphers 25 Years of Molecular Hematology Evolution—From Gene Expression Profiles to Precision Diagnosis and Treatment Profiles

In the Presidential Session of the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Lars Bullinger from Charité – Universitätsmedizin Berlin delivered a keynote speech titled "From gene profiles to therapy profiles - a quarter century of molecular hematology." Combining his personal research experience with global major scientific breakthroughs, Prof. Bullinger provided a profound analysis of the evolutionary path of hematologic malignancies, represented by Acute Myeloid Leukemia (AML), from morphological classification to molecular precision diagnosis and treatment.
83% EFS Reaches New High! AIEOP-BFM Study Confirms Replacing Chemotherapy with Blinatumomab Significantly Improves Prognosis in High-Risk B-ALL Pediatric Patients

83% EFS Reaches New High! AIEOP-BFM Study Confirms Replacing Chemotherapy with Blinatumomab Significantly Improves Prognosis in High-Risk B-ALL Pediatric Patients

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Martin Schrappe, on behalf of the AIEOP-BFM consortium, announced the latest analysis data from the Phase III randomized controlled clinical trial AIEOP-BFM ALL 2017. This study aimed to explore the clinical benefits of using the bispecific antibody Blinatumomab to completely replace two cycles of high-intensity toxic chemotherapy in newly diagnosed pediatric and adolescent patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL). The results showed that this strategy not only significantly improved the event-free survival (EFS) rate of patients but also substantially reduced treatment-related toxicity and transplant-related mortality.
As of the data analysis date, a total of 17 patients were enrolled. The median age was 63 years, the median number of prior treatment lines was 4, and 65% of patients had received at least one prior allogeneic hematopoietic stem cell transplant.

As of the data analysis date, a total of 17 patients were enrolled. The median age was 63 years, the median number of prior treatment lines was 4, and 65% of patients had received at least one prior allogeneic hematopoietic stem cell transplant.

Although progress has been made in the treatment of Acute Myeloid Leukemia (AML) over the past few decades, clinical options remain very limited for patients with relapsed/refractory (R/R) disease. Chimeric Antigen Receptor T-cell (CAR-T) therapy has achieved revolutionary breakthroughs in B-cell malignancies; however, its application in the field of AML has faced significant challenges due to limitations in target selection, patient T-cell quality, and potential toxicities (such as long-term bone marrow suppression).
Precision Subtyping and BTKi Upfront: Professor Mats Jerkeman Details MCL Guideline Updates and Clinical Pathway Optimization

Precision Subtyping and BTKi Upfront: Professor Mats Jerkeman Details MCL Guideline Updates and Clinical Pathway Optimization

In the recent European Hematology Association (EHA) Annual Meeting, Professor Mats Jerkeman from Lund University, Sweden, provided an in-depth interpretation of the diagnosis and latest treatment guidelines for Mantle Cell Lymphoma (MCL). With the release of results from several large-scale clinical trials (such as TRIANGLE, ECHO, SHINE, etc.), the treatment landscape for MCL is undergoing a transformation from traditional chemo-immunotherapy to precision targeted therapies centered on BTK inhibitors (BTKi).